<DOC>
	<DOCNO>NCT00945126</DOCNO>
	<brief_summary>The aim study investigate feasibility toxicity allogeneic haploidentical unrelated transplantation CD3/CD19 deplete stem cell associate reduced standard condition regimen pediatric patient malignant non-malignant high-risk disease , allogeneic stem cell transplantation represent possible therapy option human leukocyte antigen ( HLA ) compatible related donor available .</brief_summary>
	<brief_title>Allogeneic Stem Cell Transplantation Pediatric Patients With Malignant Non-malignant High-risk Diseases</brief_title>
	<detailed_description />
	<criteria>Patients age 0 30 year Written inform consent patient and/or parent guardian Patients Karnofsky Index &gt; 60 % Malignant disease : acute lymphoblastic leukemia acute myeloid leukemia myelodysplastic syndrome chronic myeloid leukemia accord standard indication solid tumor ( e.g . neuroblastoma recurrence , softtissue sarcoma , Ewing 's sarcoma , osteosarcoma , hepatoblastoma ) . Non malignant disease : acquire anemia ( e.g . severe aplastic anemia , particularly severe Evans syndrome ) congenital anemia ( e.g . thalassemia sickle cell anemia ) Women reliable contraception method appropriate Participation clinical trial Patients , parent , guardian unable understand nature , importance implication procedure Pregnant nursing woman Patients underwent stem cell transplantation last 250 day Patients kidney , heart liver insufficiency</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Allogeneic stem cell transplantation pediatric patient</keyword>
	<keyword>CD3/CD19 deplete stem cell</keyword>
	<keyword>malignant non-malignant high risk disease</keyword>
</DOC>